A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children With Pulmonary Arterial Hypertension
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms TOMORROW
- Sponsors Actelion Pharmaceuticals
- 26 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 24 Aug 2017.
- 29 Jun 2017 Planned End Date changed from 1 Jul 2022 to 14 Jul 2022.
- 29 Jun 2017 Planned primary completion date changed from 1 Jul 2022 to 14 Jul 2022.